acetaminophen has been researched along with amphotericin b in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cramer, RL; Fuhs, DW; Goodwin, SD; Grasela, TH; Moriarty, VP; Walawander, MK | 1 |
| Hennigar, GR | 1 |
| Cleary, JD; Goodwin, SD; Grasela, TH; Taylor, JW; Walawander, CA | 1 |
| Szegedi, J | 1 |
| Boskovic, D; Cetkovsky, P; David, K; Krivan, G; Lu, M; Mrsic, M; Paterson, DL; Sterba, J; Weng, XH; Zhu, LP | 1 |
| Amekyeh, H; Billa, N; Chin, SL; Yuen, KH | 1 |
| Amekyeh, H; Billa, N; Lim, SC; Yuen, KH | 1 |
| Amekyeh, H; Billa, N; Roberts, C | 1 |
| Barker, PJ; Hoshitsuki, K; Inaba, H; Molinelli, AR; Rubnitz, JE | 1 |
| Amekyeh, H; Billa, N | 1 |
3 review(s) available for acetaminophen and amphotericin b
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Prospective surveillance of intravenous amphotericin B use patterns.
Topics: Acetaminophen; Amphotericin B; Diphenhydramine; Drug Therapy, Combination; Female; Hospitals, Teaching; Humans; Infusions, Intravenous; Male; Middle Aged; Premedication; Product Surveillance, Postmarketing; Prospective Studies; Risk Factors; Time Factors | 1990 |
[Renal insufficiency caused by medicines, diagnostic processes, toxins].
Topics: Acetaminophen; Acute Kidney Injury; Aminoglycosides; Amphotericin B; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Cisplatin; Contrast Media; Cyclosporine; Foscarnet; Humans; Hungary; Ischemia; Kidney; Kidney Function Tests; Pentamidine; Prognosis | 2007 |
2 trial(s) available for acetaminophen and amphotericin b
| Article | Year |
|---|---|
Prospective surveillance of intravenous amphotericin B use patterns.
Topics: Acetaminophen; Amphotericin B; Diphenhydramine; Drug Therapy, Combination; Female; Hospitals, Teaching; Humans; Infusions, Intravenous; Male; Middle Aged; Premedication; Product Surveillance, Postmarketing; Prospective Studies; Risk Factors; Time Factors | 1990 |
Pretreatment regimens for adverse events related to infusion of amphotericin B.
Topics: Acetaminophen; Adrenal Cortex Hormones; Amphotericin B; Diphenhydramine; Fever; Headache; Heparin; Humans; Incidence; Infusions, Intravenous; Nausea; Premedication; Prospective Studies; Shivering; Thrombophlebitis | 1995 |
17 other study(ies) available for acetaminophen and amphotericin b
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Iatrogenic drug toxicity.
Topics: Acetaminophen; Age Factors; Amphotericin B; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Hemolysis; Humans; Isoniazid; Kidney Diseases; Methotrexate; Pharmaceutical Preparations; Probability; Time Factors | 1985 |
Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
Topics: Acetaminophen; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Cholesterol Esters; Drug Combinations; Female; Histamine Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Mycoses | 2008 |
A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats.
Topics: Acetaminophen; Amphotericin B; Animals; Calorimetry, Differential Scanning; Gastrointestinal Transit; Lipids; Microscopy, Electron, Scanning; Nanoparticles; Rats; Sulfasalazine | 2015 |
Effect of Food Status on the Gastrointestinal Transit of Amphotericin B-Containing Solid Lipid Nanoparticles in Rats.
Topics: Acetaminophen; Amphotericin B; Animals; Chemistry, Pharmaceutical; Digestion; Food; Gastric Emptying; Gastrointestinal Tract; Gastrointestinal Transit; Lipids; Male; Nanoparticles; Rats; Rats, Sprague-Dawley; Sulfapyridine | 2016 |
Correlating gastric emptying of amphotericin B and paracetamol solid lipid nanoparticles with changes in particle surface chemistry.
Topics: Acetaminophen; Administration, Oral; Amphotericin B; Drug Carriers; Drug Stability; Gastric Emptying; Humans; Lipids; Models, Biological; Nanoparticles; Surface Properties | 2017 |
Metabolic Acidosis in a Pediatric Patient with Leukemia and Fungal Infection.
Topics: Acetaminophen; Acidosis; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Antipyretics; Candida; Candidiasis; Child; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute; Male; Pyrrolidonecarboxylic Acid | 2020 |
Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil.
Topics: Acetaminophen; Amphotericin B; Cacao; Drug Carriers; Drug Compounding; Freeze Drying; Hydrophobic and Hydrophilic Interactions; Lipids; Nanoparticles; Pharmaceutical Preparations; Plant Oils; Sulfasalazine; Waxes | 2021 |